Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that results from two pralatrexate (PDX) studies were presented as posters during the 50 th Annual Meeting of the American Society of Hematology (ASH), on December 6, 2008, in San Francisco, California. One poster reports interim data from a Phase 1 trial of pralatrexate as a single agent in patients with relapsed or refractory cutaneous ...
More...
More...